Edwards Lifesciences Corp (EW)

Orthopedic, Prosthetic & Surgical Appliances & Supplies · market cap $50.9B · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-29 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Edwards Lifesciences (EW) is a ~$54.6B market-cap medical technology company headquartered in Irvine, CA, specializing in tissue heart valves and transcatheter structural heart disease technologies with 16,000 employees and global manufacturing operations. The company generates roughly $6B in annual revenue with consistent R&D investment around $1B per year. The next identified catalyst is a Q2 2026 earnings report on July 23, rated modest importance.

The catalyst path

2026-10-29 (est.)Earningsimp 5/10

Pipeline

No pipeline data.

Price & technical context

3-month

-6.2%

6-month

+7.8%

12-month

+11.8%

52-wk range

$72.65–$95.18

vs 50-day MA

-2.4%

vs 200-day MA

+1.4%

Realized vol

25.2%

Max drawdown

-13.2%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for EW (10-K, 10-Q, S-3, 13D/G, Form 4)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.